BioCentury
ARTICLE | Clinical News

Baricitinib: Phase III data

December 22, 2014 8:00 AM UTC

Top-line data from the double-blind, international Phase III RA-BEACON trial in 527 patients with moderately to severely active RA who had previously failed =1 tumor necrosis factor (TNF) inhibitor s...